Clinical Trials/JPRN-UMIN000029315

JPRN-UMIN000029315

Recruiting

未知

Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancer - GOZILA Study

ational Cancer Center Hospital East0 sites7,000 target enrollmentDecember 1, 2017

Conditionsnresectable advanced or reccurrent gastrointestinal malignancies

Overview

Phase: 未知
Intervention: Not specified
Conditions: nresectable advanced or reccurrent gastrointestinal malignancies
Sponsor: ational Cancer Center Hospital East
Enrollment: 7000
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 1, 2017

End Date

March 31, 2027

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

ational Cancer Center Hospital East

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\.Lymphoid malignancy 2\.Have a history of bone marrow or organ transplantation; 3\.Are pregnant; or 4\.Are judged by the study doctor to be ineligible for the study for any other reason.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIson-small cell Lung Cancer

JPRN-UMIN000023248PHRF122

Not yet recruiting

Clinical efficacy of Liquid biopsy for acquired resistance to afatinib in EGFR positive NSCLCEGFR mutation positive NSCLC

JPRN-UMIN000025112Aichi cancer center100

Exploratory research of liquid biopsy for patients with cancercancer

JPRN-UMIN000033269Cancer Precision Medicine Center Cancer Institute,800

Not yet recruiting

Endoscopic exploration for the incidence of gastrojejunal anastomotic ulcer in patients undergoing subtotal stomach preserving pancreatoduodenectomyPatients who underwent subtotal stomach preserving pancreatoduodenectomy (SSPPD)

JPRN-UMIN000035752agoya University Graduate School of Medicine80

Active, not recruiting

tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10025055Term: Lung cancer non-small cell stage IV Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]

CTIS2024-511317-38-00Fundacion GECP33